Stocks Health care MXCT
NASDAQ · Health careMaxcyte, Inc. (MXCT)
Maxcyte, Inc. brought in $31.1M of revenue over the twelve months to June 30, 2026, down 13.2% from a year earlier. It posted a net loss of $35.6M. In fiscal 2025 capital spending exceeded operating cash flow by $36.2M. At June 30, 2026 it held $15M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Maxcyte, Inc.
- Net worth
- Maxcyte, Inc. has a market value (market cap) of $123.8M at the latest share price, and shareholders' equity of $158.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $33M (-14.5% year on year), with a net loss of $44.6M. Over the 12 months to June 30, 2026: revenue $31.1M, net loss $35.6M.
- Cash flow
- In fiscal 2025 operations used $34.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Maxcyte, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Maxcyte, Inc. does
Maxcyte, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker MXCT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $33M | -$44.6M | -$0.42 | -$36.2M |
| 2024 | $38.6M | -$41.1M | -$0.39 | -$29.3M |
| 2023 | $41.3M | -$37.9M | -$0.37 | -$25.4M |
| 2022 | $44.3M | -$23.6M | -$0.23 | -$33.3M |
| 2021 | $33.9M | -$19.1M | -$0.21 | -$14.5M |
| 2021 | $26.2M | -$11.8M | -$0.17 | -$10.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MXCT ranks in Health care
Latest SEC filings
What Maxcyte, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Activist stake (5% or more) SCHEDULE 13D
- October 15, 2026Activist stake (5% or more) SCHEDULE 13D
- October 14, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 15% to $7.3M versus the same quarter last year; diluted EPS -$0.08 versus -$0.12.
- August 12, 2026
- August 4, 2026Activist stake (5% or more) SCHEDULE 13D
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 17, 2026
- June 16, 2026
- May 14, 2026Activist stake (5% or more) SCHEDULE 13D
Insider trades
What the people running Maxcyte, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 17, 2026 | Al-Wakeel Yasir B.Director | Received as pay | 30,421 | - |
| June 17, 2026 | Balthrop Patrick JDirector | Received as pay | 30,421 | - |
| June 17, 2026 | Brooke William WDirector | Received as pay | 30,421 | - |
| June 17, 2026 | Collins CynthiaDirector | Received as pay | 30,421 | - |
| June 17, 2026 | Douglas RichardDirector | Received as pay | 30,421 | - |
| June 17, 2026 | Erck Stanley CDirector | Received as pay | 30,421 | - |
| June 17, 2026 | Hemrajani RekhaDirector | Received as pay | 30,421 | - |
| June 17, 2026 | Johnston John JosephDirector | Received as pay | 30,421 | - |
Who owns MXCT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Capricorn Fund Managers Ltd13G, passive | 7.7% | February 5, 2026 |
| Liontrust Investment Partners LLP13D, may seek influence | 5% | October 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 123 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Capricorn Fund Managers Ltd | 8,200,000 | 0 |
| Vitruvian Partners LLP | 5,043,356 | 0 |
| Vanguard Capital Management LLC | 4,031,284 | +49,468 |
| Morgan Stanley | 3,694,049 | +5,918 |
| Mudita Advisors LLP | 3,370,689 | 0 |
| BlackRock, Inc. | 3,060,960 | -5,737,513 |
| Brooklands Fund Management Ltd | 2,848,083 | +658,063 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,773,554 | 0 |
| Cadian Capital Management, LP | 2,201,166 | +478,224 |
| Peapod Lane Capital LLC | 2,125,752 | +793,559 |
| Renaissance Technologies LLC | 1,910,800 | -82,400 |
| Aqr Capital Management LLC | 1,882,776 | +661,594 |
| Jane Street Group, LLC | 1,563,003 | +1,542,434 |
| Two Sigma Investments, LP | 1,462,941 | +854,779 |
| Geode Capital Management, LLC | 1,326,914 | -1,035,758 |
| RBF Capital, LLC | 1,322,443 | new |
| Goldman Sachs Group Inc | 1,241,943 | +82,924 |
| Millennium Management LLC | 1,204,921 | +1,161,862 |
| Nano Cap New Millennium Growth Fund L P | 1,200,000 | +200,000 |
| Marshall Wace, Llp | 1,014,778 | +915,866 |
Insiders
11 insiders reported holding 2,230,417 shares in total, about $2.7M at the last price.
| Holder | Shares |
|---|---|
| Masoud MaherPresident and CEO, Director | 475,000 |
| Erck Stanley CDirector | 428,749 |
| Douglas RichardDirector | 260,998 |
| Johnston John JosephDirector | 201,581 |
| Ahuja ParmeetChief Financial Officer | 187,500 |
| Brooke William WDirector | 181,300 |
| Swirsky Douglas JCHIEF FINANCIAL OFFICER | 151,669 |
| Collins CynthiaDirector | 111,310 |
| Al-Wakeel Yasir B.Director | 80,998 |
| Balthrop Patrick JDirector | 80,998 |
Questions about MXCT
What does Maxcyte, Inc. do?
Maxcyte, Inc. is a company in the Health care sector, listed on NASDAQ as MXCT. Its shares trade on NASDAQ under the ticker MXCT.
What is Maxcyte, Inc.'s net worth?
Maxcyte, Inc. has a market value (market cap) of $123.8M at the latest share price, and shareholders' equity of $158.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Maxcyte, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $35.6M on revenue of $31.1M.
How much revenue does Maxcyte, Inc. make?
Over the twelve months to June 30, 2026 Maxcyte, Inc. reported revenue of $31.1M. That is 13.2% less than a year earlier.
When did Maxcyte, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake (5% or more) from November 2, 2026.
When is Maxcyte, Inc.'s next earnings report?
Maxcyte, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MXCT with
Follow MXCT
Get an email when Maxcyte, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Maxcyte, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.